CClinicalTrials.gg
RecruitingNCT07190859Updated Sep 24, 2025

Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic

An interventional study of L. reuteri and Placebo in Infantile Colic, sponsored by BioGaia AB. Recruiting at 4 sites in Bulgaria. Open to participants aged 3 Weeks to 12 Weeks. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by BioGaia AB · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
3 Weeks to 12 Weeks
Sex
All
01

Study summary

This is a double-blind, randomized, placebo-controlled, parallel-group study in infants with colic with the primary objective to evaluate crying and fussing time.

02

Conditions studied

  • Infantile Colic

Browse trials for

03

Who can participate

Ages eligible
3 Weeks to 12 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Aged between 3-12 weeks at screening.
  2. Gestational age 37+0 weeks - 42+0 weeks at birth.
  3. Birth weight appropriate for gestational age (AGA - weight between 10th and 90th percentile) or Large for Gestational Age (LGA - weight above the 90th percentile) determined using WHO Weight-for Age percentile guides.
  4. Parents/caregivers/legal guardians are >18 years.
  5. Exclusively or predominantly breastfed infants (> 50 % breast fed).
  6. Willing to maintain current feeding patterns (not change formula/not change ratio of formula:breast milk etc.).
  7. Readiness and the opportunity for parents/caregivers/legal guardians to fill out a study diary, questionnaires.
  8. Infantile colic diagnosed according to Rome IV criteria (face-to-face consult with a physician, parents/caregivers/legal guardians must report that their infant has cried or fussed for 3 or more hours per day, during 3 or more days in the preceding week). At Visit 2, this will be confirmed by Baby's Day Diary®, at least one 24-hour period should show 3 or more hours of crying/fussing time.
  9. Parents/caregivers/legal guardians with ability to understand and comply with the requirements of the study, as judged by the Investigator.
  10. Parents/caregivers/legal guardians willing and able to give informed consent for their and their infant's participation in the study.
  11. The mother of the infant must be willing to attend Visit 2 (Day 0), Visit 3 (Day 8), and Visit 4 (Day 22).
  12. Infant is considered healthy, in the opinion of the investigator following physical exam.

Exclusion criteria

Exclusion Criteria:

  1. Infants with severe gastroesophageal reflux (throwing up or spitting up more than a teaspoon of milk > 8 times daily, projectile, bilious or bloody emesis).
  2. Infants with failure to thrive, intrauterine growth retardation, haematochezia (blood in the stools), diarrhoea (watery stools that takes the shape of a container > 12x in breastfed and >5 in partially breastfed infants daily), or fever (38.0 degrees), as reported by parents/caregivers/ legal guardians.
  3. Infants with congenital heart disease, immunodeficiency, asplenia, cancer, cystic fibrosis, and those with liver disease.
  4. Infants with reported exposure to probiotics in the 7 days prior to Screening Visit (V1) and throughout the study period.
  5. Infants with reported exposure to oral and/or systemic antibiotics in the 7 days prior to Screening Visit (V1) and throughout the study period.
  6. Infants with reported exposure to medications, therapies, or products with the aim to relieve infantile colic including proton pump inhibitors in the 7 days prior to Screening Visit (V1) and throughout the study period.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    L. reuteri

    Dietary supplement: L. reuteri

    Dietary Supplement: L. reuteri

  • Placebo comparator
    Placebo

    Placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementL. reuteri

    Supplementation with drops containing L. reuteri once daily for 21 consecutive days

  • Dietary supplementPlacebo

    Supplementation with identical drops without L. reuteri once daily for 21 consecutive days

05

What researchers measure

Primary outcomes

  1. Crying and fussing time

    Change in mean crying and fussing time as assessed by the Baby's Day Diary

    Time frame: From baseline to Day 7

Secondary outcomes

  1. Crying and fussing time

    Change in mean crying and fussing time as assessed by the Baby's Day Diary

    Time frame: From baseline up to Day 21

  2. Number of responders

    Proportion of responders defined as reduction of daily average crying time with 50 % compared to baseline

    Time frame: From baseline up to Day 21

  3. Family Quality of Life

    Change in family QoL measured by the PedsQL Family Impact Module (Acute) - Total Score

    Time frame: From baseline up to Day 21

  4. Sleeping time

    Change in mean sleeping time as assessed by Baby´s Day Diary

    Time frame: From baseline up to Day 21

  5. Maternal depression

    Change in maternal depression as assessed by the Edinburgh Postnatal Depression Scale Total Score

    Time frame: From baseline up to Day 21

06

Study locations

4 of 4 sites recruiting
  • UMHAT Deva Maria
    Burgas, 8127, Bulgaria
    Recruiting
  • Medical Centre Asklepiy OOD
    Dupnitsa, 2600, Bulgaria
    Recruiting
  • AIPSMP
    Stara Zagora, 6000, Bulgaria
    • Stefan Banov, MD · Contact · stefan.banov@abv.bg · +359 888 708 022
    • Stefan Banov, MD · Principal investigator
    Recruiting
  • Ipsmp Eood
    Stara Zagora, 6000, Bulgaria
    • Margarita Syarova, MD · Contact · margaritakoleva@hotmail.com · +359 888 788 860
    • Margarita Ganeva Syarova, MD · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07190859
Lead sponsor
BioGaia AB
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Aug 4, 2025
Primary completion
Feb 17, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Sep 24, 2025

Study contacts

Sanna Nyström, PhD
Contact
sny@biogaia.se
+46761483866
Petra J Lierud
Contact
pjl@biogaia.se
+46724504400

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion